TABLE 1.

Biosimilar Products Approved by the European Medicine Agency ¹²

Name	Nonproprietary Name	Indications	Date of Approval
Abseamed	Epoetin alfa	Anemia, cancer, chronic kidney failure	8/28/2007
Binocrit	Epoetin alfa	Anemia, chronic kidney failure	8/28/2007
Epoetin Alfa Hexal	Epoetin alfa	Anemia, cancer, chronic kidney failure	8/28/2007
Retacrit	Epoetin zeta	Anemia, autologous blood transfusion, cancer, chronic kidney failure	12/18/2007
Silapo	Epoetin zeta	Anemia, autologous blood transfusion, cancer, chronic kidney failure	12/18/2007
Biograstim	Filgrastim	Cancer, hematopoietic stem cell transplantation, neutropenia	9/15/2008
Filgrastim Hexal	Filgrastim	Cancer, hematopoietic stem cell tnsplantation, neutropenia	2/6/2009
Grastofil	Filgrastim	Neutropenia	10/18/2013
Ratiograstim	Filgrastim	Cancer, hematopoietic stem cell tansplantation, neutropenia	9/15/2008
Nivestim	Filgrastim	Cancer, hematopoietic stem cell transplantation, neutropenia	6/8/2010
Tevagrastim	Filgrastim	Cancer, hematopoietic stem cell transplantation, neutropenia	9/15/2008
Zarzio	Filgrastim	Cancer, hematopoietic stem cell transplantation, neutropenia	2/6/2009
Ovaleap	Follitropin alfa	Anovulation	9/27/2013
Inflectra	Infliximab	Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, Crohn’s disease, psoriasis, akylosing spondylitis	9/10/2013
Remsima	Infliximab	Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, Crohn’s disease, psoriasis, akylosing spondylitis	9/10/2013
Omnitrope	Somatropin	Pituitary dwarfism, Prader-Willi syndrome, Turner syndrome	4/12/2006

Note: The medications listed in this table are not all distinct molecules. For example, there are only 2 biosimilar epoetins (epoetin alfa, marketed as Abseamed, Binocrit, and Epoetin Alfa Hexal, and epoetin zeta, marketed as Retacrit and Silapo).